Inhibition of eosinophil activation through A3 adenosine receptor antagonism
US5646156A · kind A · utility
36Cited by
3References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 25, 1994 |
| Grant date | Jul 8, 1997 |
| Priority date | — |
| Expiry date | Apr 25, 2014 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention concerns the identification on eosinophils of the A3 adenosine receptor subtype and the blockade of said receptor in order to achieve inhibition of eosinophil activation and degranulation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.